# Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes

> **NCT00106366** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 389 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** insulin detemir
- **DRUG:** insulin glargine
- **DRUG:** insulin aspart

## Key facts

- **NCT ID:** NCT00106366
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2005-12
- **Final completion:** 2005-12
- **Target enrollment:** 389 (ACTUAL)
- **Last updated:** 2017-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00106366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00106366, "Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00106366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*